Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Using continuous glucose monitoring data in daily clinical practice

Thomas W. Martens, MD, Gregg D. Simonson, PhD and Richard M. Bergenstal, MD
Cleveland Clinic Journal of Medicine October 2024, 91 (10) 611-620; DOI: https://doi.org/10.3949/ccjm.91a.23090
Thomas W. Martens
Medical Director, International Diabetes Center, HealthPartners Institute, Minneapolis, MN; Consultant, Department of Internal Medicine, Park Nicollet Clinic Brooklyn Center, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Gregg D. Simonson
Director of Care Transformation and Training, International Diabetes Center, HealthPartners Institute, Minneapolis, MN; Assistant Professor, Department of Family Medicine, University of Minnesota Medical School, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard M. Bergenstal
Executive Director, International Diabetes Center, HealthPartners Institute, Minneapolis, MN; Clinical Professor, Department of Medicine, University of Minnesota, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Example of an Ambulatory Glucose Profile Report. (A) The time-in-ranges graph quickly shows whether glycemic goals are being met and whether action is needed. Average glucose and glucose management indicator metrics provide additional information about the need to take action. Glucose variability reports variations over the course of the report period. Increased variability is a risk factor for hypoglycemia. (B) The ambulatory glucose profile curve presents a 24-hour picture of all glucose readings collected during the report period. (C) Ambulatory daily glucose profiles are thumbnails of daily values.

    ©2024 International Diabetes Center, Minneapolis, MN. Used with permission. Visit AGPreport.org for more information.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Patient’s Ambulatory Glucose Profile Report.

    ©2024 International Diabetes Center, Minneapolis, MN. Used with permission. Visit AGPreport.org for more information.

Tables

  • Figures
    • View popup
    TABLE 1

    Currently available continuous glucose monitoring systems

    Type of systemDescriptionExamples
    Real-timePatient-owned
    Measures and displays data continuously (real-time)
    Stores data for retrospective analysis
    Freestyle Libre 3
    Dexcom G6 and G7, Stelo (over the counter)
    Guardian 3 and 4 and Simplera
    Eversense E3
    Intermittently scannedPatient-owned
    Measures glucose continuously but only displays data when swiped by a reader or smartphone
    Also known as “flash” glucose monitoring
    Freestyle Libre 2, Rio (over the counter)
    ProfessionalClinic-owned system placed on patient in office
    Typically worn for 7–14 days
    Glucose data may be blinded (both systems) or unblinded (Dexcom G6 Pro) to the patient
    Provides data to support medication and lifestyle changes, guide shared decision-making, and identify hypoglycemia
    Freestyle Libre Pro
    Dexcom G6 Pro
    • View popup
    TABLE 2

    Glucose targets in healthy and at-risk adults

    Glucose valuesTarget levels
    Healthy nonpregnant adultsOlder and high-risk adults
    Time above range
    > 250 mg/dL< 5%< 10%
    > 180 mg/dL< 25%< 50%a
    Time in range
    70–180 mg/dL> 70%> 50%
    Time below range
    < 70 mg/dL< 4%b< 1%
    < 54 mg/dL< 1%NA
    • ↵a Includes values > 250 mg/dL.

    • ↵b Includes values < 54 mg/dL.

    • Based on information from reference 15.

    • View popup
    TABLE 3

    Case presentation: clinical data

    Demographics
    Male, age 65
    Body mass index: 42.7
    Blood pressure: 127/75 mm Hg
    Social history: single, no children, retired
    Medical history
    22-year history of type 2 diabetes
    Hypertension
    Hypercholesterolemia
    Diabetic neuropathy
    Diabetic retinopathy
    Peripheral vascular disease
    Health habits
    Nonsmoker, occasional alcohol
    No regular physical activity
    Eats 3 meals per day, often with evening snacks
    Current diabetes medications
    Metformin extended release 1,000 mg 2 times per day
    Dulaglutide 4.5 mg (maximum dose) once weekly
    Insulin glargine 60 units/day at bedtime
    Insulin lispro 10 units with meals
    Laboratory results
    Hemoglobin A1c 8.5% (reference range 4–5.6)
    Fasting blood glucose 165 mg/dL (70–99)
    Estimated glomerular filtration rate > 60 mL/minute/1.73 m2
    • View popup
    TABLE 4

    Coding for continuous glucose monitoring

    CPT codeDescriptionComments
    95249Personal (patient-owned) CGM: sensor placement, hook-up, calibration, patient training, and printoutOne-time code for initial start-up and education
    95250Professional CGM (office-owned CGM), sensor placement, hook-up, calibration, patient training, removal of sensor, and printoutBilling code covers the cost of sensors and placement by clinician/staff
    95251CGM data analysis and interpretation with report by clinicianCan be billed no more frequently than every 30 days
    Coding guidelines
    72 hours of data are required for billing any of these codes.
    -25 modifier for CGM codes can be used if billing for CGM interpretation on the same day as a Problem Visit code (99212-99215).
    If a significant and separately identifiable service took place:
    • 99212-99215: Pre-CGM evaluation (+) -25 95249: CGM start-up and instruction

    • 99212-99215: E and M code for problem visit (+) -25 95251: CGM analysis, interpretation, and report.

    • CGM = continuous glucose monitoring; CPT = current procedural terminology

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 91 (10)
Cleveland Clinic Journal of Medicine
Vol. 91, Issue 10
1 Oct 2024
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Using continuous glucose monitoring data in daily clinical practice
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Using continuous glucose monitoring data in daily clinical practice
Thomas W. Martens, Gregg D. Simonson, Richard M. Bergenstal
Cleveland Clinic Journal of Medicine Oct 2024, 91 (10) 611-620; DOI: 10.3949/ccjm.91a.23090

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Using continuous glucose monitoring data in daily clinical practice
Thomas W. Martens, Gregg D. Simonson, Richard M. Bergenstal
Cleveland Clinic Journal of Medicine Oct 2024, 91 (10) 611-620; DOI: 10.3949/ccjm.91a.23090
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • OVERVIEW OF CGM DEVICES
    • EVIDENCE AND GUIDELINES ARE EVOLVING
    • THE POWER OF CGM: 2 TYPES OF DATA
    • THE AMBULATORY GLUCOSE PROFILE: 3 STEPS
    • CASE PRESENTATION
    • CGM CLINICAL PEARLS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Continuous glucose monitoring: High-tech devices still need some low-tech backup
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Diabetes
  • Endocrinology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire